The B-rapid accelerating fibrosarcoma (BRAF) (dabrafenib, vemurafenib, encorafenib) and mitogen extracellular signal-regulated kinase (MEK) inhibitors (trametinib, cobimetinib, binimetinib) are serine-threonine kinase inhibitors that are active against V600 mutations in melanoma and colorectal carcinomas [39]. This evidence concerns the gene BRAF and melanoma.